

**INTERNATIONAL PHARMA LICENSING SYMPOSIUM (IPLS):
CONTRIBUTION OF SPEAKERS FROM JAPAN**

1st IPLS at Down Hall Country House Hotel, UK on September 22-24, 1997

Blockbusters and candidates from Japan

Keiji Nakamura, Ph.D. Pharma Forum Institute

Determining factors for royalty rates

Motohiro Yamazaki, Ph.D. General Manager, Licensing Division Tanabe Seiyaku

Future disease patterns in Japan

Toshio Nagae Director, Strategic Planning Rhone-Poulenc Rorer Japan

2nd IPLS at Conference Center, Intercontinental Hotel, Yokohama on Sept 21-23 1998

Present and future therapeutic economics in Japan

Prof. Shuzo Nishimura Kyoto University Faculty of Economics

Future healthcare, medical insurance and drug pricing policy in Japan

Motoyuki Fujii, Ph.D. Senior executive director Japan Health Science Fdn

Interfacing with US and Japanese governments officials: Dealing with the government on reform in Japan

Carl F. Tausch, LLD Japan representative of PhRMA

Cracking the Japanese pharmaceutical market

P. Reed Maurer President Nippon Pharma Promotion

Role of OTC and generic drugs in future healthcare in Japan

Toritsugu Noro Corporate management & development Taisho

OTC and herb medicine in Japan

*Prof. Hiroshi Saito Pharmacology Nihon University Sch Pharmac Science
(emeritus professor of Tokyo University)*

Current issues affecting pharmaceutical licensing in Japan

Motohiro Yamasaki, Ph.D. General manager licensing Division Tanabe

Evaluation of marketing values of a new chemical entity

Toshio Nagae Director marketing division Rhone Poulenc Rorer Japan

Pharmaceutical industry pulse in Japan – Leading companies have begun to undergo keen global competition

Tetsuo Kitagawa, Ph.D. Vice president JP Morgan Investment Management Tokyo

Probable trade secrets flow-out in NDA investigation process and how it can be prevented

Toshiharu Ishida Representative TCL Institute, Tokyo

3rd IPLS at Grand Hotel International Paris, on October 11-13 1999

Constraints and issues in Japan : impacts of ICH both at regulatory and company level

*Youichi Maeda Manager Corporate planning administration Daiichi
New drug development activity of Takeda Europe*

Syuji Higuchi, Ph.D. Managing director Takeda Europe R & D Ctr UK

4th IPLS at Hotel Excelsior Venice, on November 6-8 2000

Revolutionary changes and foresight in the market place in Japan

*Motohiro Yamasaki, Ph.D. Executive Officer & Vice Chairman Strategic Corporate
Development Committee, Tanabe Seiyaku*

Value optimisation of NCEs reflecting future disease patterns

Toshio Nagae Corporate officer, Head of Medical marketing, Aventis Japan

Challenges to the Japanese pharmaceutical industry

Koichi Kato, Ph.D. Director of Licensing, Takeda

5th IPLS Toshi Center Hotel Tokyo, on September 17-19 2002

Future pharmaceutical industry

Touichi Takenaka, Ph.D. Yamanouchi, President and CEO

Recent developments in NTA policies that effects the restructuring of Japan Pharma indust.

Setsuko Fukushima KPMG Peat Marwick, Director

Value creation through partnering

Amy Akaike Eli Lilly Japan Plan Progr Pdt Mgr Coordinat

Successful merger between a Japanese and an European company based in Germany

Manfred Basch, B Rossi & T Kitano Schering AG & Nihon Schering

International compatibility of Japanese pharmaceutical industry

Hidemaru Yamaguchi Nikko Solomon Barney Tokyo Director

Healthcare reform and the climate for drug innovation

Carl F Taeusch JD Pharmacia Tokyo Law Publ Policy Sen Director

Life science frontiers in the 21st century & translational research platform for genomic medicine

Kenichi Arai, M.D., Ph.D. Inst Med Sci Univ Tokyo Dean & Professor

Japan biotech venture companies and venture capitals

Hiroko Hayase, Ph.D. BioPharmaLicensing, President

New technology revolutionizes healthcare: bio-electronics and distant diagnosis

Itaru Tanimura So-net M3 (Sony), CEO & President

New venture company in Osaka University: MedGene Bioscience Inc

Ryuichi Morishita, M.D., Ph.D. Osaka Univ Gene Therap, Dir, Assoc Prof

Chymase and its inhibitors: functional roles and therapeutic application

Mizuo Miyazaki, M.D., Ph.D. Osaka Medical Univ Pharmacol, Prof

Drug discovery by rational drug design

Akiko Itai, Ph.D. Inst Med Molec Design, President, Professor

Recent progress in antibody medicine: TransChromo (TC) mouse

Isao Ishida, Ph.D. Kirin Pharmaceutical, Business Devel Manager

A fusion of nanotechnology & biotechnology

Ichiro Nakatomi, Ph.D. Nano Carrier, CEO & President

Current issues in clinical trials in Japan

Kiyoshi Kurokawa, M.D.,Ph.D. Tokai UnivSch Med & Hosp, Dean & Professor

Paradigm shift of clinical development in Japan – How to accelerate clinical study –

Kazuo Nakamera CMIC Tokyo, CEO & Chairman Japan

Pharmaceutical market in Japan: future growth and disease patterns

Toshio Nagae Avents, Tokyo Sales Mkt Corporate Officer

Corporate bioscience publication in Japan: 1981 – 2000

Masafumi Yoshimoto, Ph.D. Sankyo, Licensing Product Portfolio Dept Director

6th IPLS at Hilton in Geneva, September 16-19 2003

Japan – the role of Japanese companies in the world market

Naoki Tani Fujisawa Pharmaceutical, Director Licensing & Product Acquisit.

Licensing strategy of Sankyo in the World

Masafumi Yoshimoto, Ph.D. Sankyo Pharmaceutical, Director Licensing Dpt

Introduction to Kyowa Hakko Kogyo and strategy in development

Tersushi Inada, Ph.D. Kyowa Hakko Co. Ltd, Head Licensing Dept

Changing partnership strategy reflecting the recent environment for the pharmaceutical industry

Toshio Nagae CMIC MPSS CO Ltd, President

Review of the internationalization of Japanese companies in Europe & North America

Shigeru Enomoto Takeda Chemical Industries., Senior Manager, Licensing

Co-presence of global and local companies in the future Japanese market

Masayuki Kinoshita Mitsubishi Pharma, Head Patent & Licensing Dpt

7th IPLS at Westin Palace in Madrid, September 27-30 2005

Value maximisation of pharma products reflecting development & marketing strategy

Toshio Nagae CMIC MPSS, President

Survival and licensing strategy from the Japanese middle-sized company

Kazushige Itabashi Nippon Shinyaku Corporate Officer & General Manager

Japanese biomedical engineering industry

Mime Egami ABN AMRO Director of Healthcare

Activity profile of JETRO for pharmaceutical companies

Naoyuki Maekawa JETRO Deputy Director Invest Japan Support Ctr

Takashi Nakagawa JETRO Director of Investment Promotion